Certificate of Mailing [37 CFR 1.8(a)]

I hereby certify that this paper and the documents referred to as attached ein are being deposited with the United States Postal Service on the date wn below with sufficient postage as first class mail addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

De	nise Orteqa	
Nam	e .,···	
ogʻ (Denus Ortes	

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bruce M. Bowman Group: 1600

Serial No.: 09/480,389 Group Art Unit: 1642

Filed January 11, 2000 Examiner: A. Holleran :

For Immunoassays to Detect Diseases or Disease

Susceptibility Traits

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR SECTIONS 1.56, 1.97 AND 1.98

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

March 9, 2004

Date

Sir:

The accompanying PTO Form 1449 is submitted pursuant to 37 CFR Sections 1.56, 1.97 and 1.98, directing Applicants to submit literature and information that may be considered material to the examination of the claims of an application.

Applicants respectfully submit that the instant Supplementary Information Disclosure Statement (IDS) is being submitted before a final office action under 37 CFR § 1.113. Therefore, the instant Supplementary IDS, in accordance with 37 CFR § 1.97(c).

shall be considered by the Office if filed by the applicant after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of either a final action under §1.113, or a notice of allowance under §1.311, whichever occurs first and is accompanied by either:

(2) The fee set forth in §1.17(p).

The Marchuk, D.A., <u>Current Opinion in Hematology</u>, 5:

332-338 (1998) article submitted herewith cites as reference 34

to Pece et al., <u>J. Clin. Invest.</u>, 100(10): 2568-2579 (Nov. 1997).

A copy of Pece et al., which is cited on PTO form 1449, also accompanies this Supplementary IDS.

Accompanying this statement is a request for payment by credit card of the fee as set forth in § 1.17(p). Should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Applicants respectfully submit that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]

Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the document may have an effective date which can be antedated. Applicants respectfully conclude on this point that the "prior art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references either alone or in combination with any other references would be sufficient to render any of the claims of the above-identified patent application unpatentable.

Respectfully submitted,

Æeona L. Lauder

Attorney for Applicants Registration No. 30,863

Dated: March 9, 2004

(F III			Docket Number (Optional)	Application Number		
INFORMATION DISCLOSURE CITATION			CATX-N Applicant(s) Proper M. Pomon	09/480,389		
MAR 17 20	10h zi	Use several sheets if necessary)	Filing Date	Bruce M. Boman Filing Date Group Art Unit		
	<u> </u>		January 11, 2000	1642		
PEXAMPLER T	S.	OTHER DOCUMENTS (Including Autho				
INITIAL		Marchuk, D.A., "Genetic abnormalities in her 332-338 (1998)	reditary hemorrhagic telangiectasia," C	Current Opinion in Hematology, 5:		
		332-336 (1776)				
		Pece et al., "Mutant Endoglin in Hereditary H Is Not a Deominant Negative," J. Clin. Invest.,	lemorrhagic Telangiectasia Type 1 Is To 	ransiently Expressed Intracellularly and		
			· · · · · · · · · · · · · · · · · · ·			
L.						
ŗ						
	Ì					
•	F723					
ll ll				j j		
			W			
	-					
EXAMINER	EXAMINER		DATE CONSIDERED			
		citation considered, whether or not citation is in con- copy of this form with next communication to applic		ne through citation if not in conformance and		